BR112017002580A2 - administration of nanoencapsulated bioactive antioxidants - Google Patents

administration of nanoencapsulated bioactive antioxidants

Info

Publication number
BR112017002580A2
BR112017002580A2 BR112017002580-9A BR112017002580A BR112017002580A2 BR 112017002580 A2 BR112017002580 A2 BR 112017002580A2 BR 112017002580 A BR112017002580 A BR 112017002580A BR 112017002580 A2 BR112017002580 A2 BR 112017002580A2
Authority
BR
Brazil
Prior art keywords
lutein
nanoparticles
gel
polymer
antioxidant
Prior art date
Application number
BR112017002580-9A
Other languages
English (en)
Portuguese (pt)
Inventor
M. SABLIOV Christina
E. ASTETE Carlos
BODOKI Ede
Vostinaru Oliviu
Ciprian SAMOILA Ovidiu
Dinte Elena
Original Assignee
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College filed Critical Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College
Publication of BR112017002580A2 publication Critical patent/BR112017002580A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112017002580-9A 2014-08-11 2015-08-10 administration of nanoencapsulated bioactive antioxidants BR112017002580A2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462035683P 2014-08-11 2014-08-11
US62/035,683 2014-08-11
US201562172455P 2015-06-08 2015-06-08
US62/172,455 2015-06-08
PCT/US2015/044483 WO2016025394A2 (en) 2014-08-11 2015-08-10 Delivery of bioactive, nanoencapsulated antioxidants

Publications (1)

Publication Number Publication Date
BR112017002580A2 true BR112017002580A2 (en) 2018-03-27

Family

ID=55304745

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017002580-9A BR112017002580A2 (en) 2014-08-11 2015-08-10 administration of nanoencapsulated bioactive antioxidants

Country Status (12)

Country Link
US (2) US10292943B2 (https=)
EP (1) EP3179988A4 (https=)
JP (1) JP6668327B2 (https=)
KR (1) KR102218883B1 (https=)
AP (1) AP2017009684A0 (https=)
AU (1) AU2015301945B2 (https=)
BR (1) BR112017002580A2 (https=)
CA (1) CA2992879C (https=)
EA (1) EA035620B1 (https=)
MX (1) MX388028B (https=)
WO (1) WO2016025394A2 (https=)
ZA (1) ZA201700987B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX388028B (es) * 2014-08-11 2025-03-19 Univ Louisiana State Suministro de antioxidantes bioactivos, nanoencapsulados.
WO2019148140A2 (en) * 2018-01-26 2019-08-01 Wu Joseph C Implantable biomaterials that enhance stem cell survival and function
CA3174213A1 (en) * 2019-06-14 2020-12-17 Daniela Oana Trambitas Method for micro-encapsulation of natural ingredients by means of contacting with supercritical gas
CA3181943A1 (en) * 2020-05-11 2021-11-18 Op2Lysis Slow release plasminogen activator formulation for use in the treatment of thrombotic or haemorrhagic disease
US11253481B1 (en) 2021-07-12 2022-02-22 King Abdulaziz University Self-nanoemulsifying 3D-printed tablet composition and method of use thereof
US11298321B1 (en) 2021-07-12 2022-04-12 King Abdulaziz University Methods for treating metabolic disorder
KR102824097B1 (ko) 2022-12-07 2025-06-24 주식회사 엘지생활건강 바이오틴이 담지된 나노파티클 및 이의 제조 방법, 및 이의 용도
WO2025106389A1 (en) * 2023-11-13 2025-05-22 Universitatea De Medicină Şi Farmacie Iluiu Haţieganu New forms of lutein and their uses

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0386960A3 (en) 1989-03-07 1991-10-23 American Cyanamid Company Pharmaceutical compositions useful as drug delivery vehicles and/or as wound dressings
US6573299B1 (en) 1999-09-20 2003-06-03 Advanced Medical Instruments Method and compositions for treatment of the aging eye
US6703039B2 (en) * 2000-12-06 2004-03-09 Bausch & Lomb Incorporated Reversible gelling system for ocular drug delivery
DE10141018A1 (de) * 2001-08-22 2003-03-13 Eth Zuerich Eidgenoessische Te Verwendung von negativ geladenen Phospholipiden, sowie Zusammensetzungen umfassend Phospholipide zur Behandlung des Auges
US20040009212A1 (en) 2002-01-30 2004-01-15 Pharma Power Biotec Co. Ltd. Mucoadhesive thermoresponsive medicament-carrier composition
EP1534202B1 (en) * 2002-06-05 2009-03-11 University Of Florida Research Foundation, Inc. Ophthalmic drug delivery system
MX2008004981A (es) * 2005-10-16 2008-10-17 Lycored Ltd Composiciones para el tratamiento de enfermedades de los ojos.
US9707185B2 (en) 2007-05-07 2017-07-18 Board Of Supervisors Of Louisana State University And Agricultural And Mechanical College Water-soluble nanoparticles containing water-insoluble compounds
BR112013000675B1 (pt) * 2010-07-16 2021-07-20 Universidad De Navarra Nanopartícula, processo para produzir uma nanopartícula compreendendo uma matriz de zeína e um aminoácido básico, composição e produto alimentar
JP5829685B2 (ja) * 2010-09-03 2015-12-09 サンテン・エス・エー・エス 眼の疾患を処置するための油中水型エマルション
BR112013021731A2 (pt) * 2011-02-25 2016-11-01 Univ South Dakota nanopartícula;composição farmacêutica ou cosmética;utilização; método para melhorar a estabilidade de um retinóide;método para melhorar a dispersibilidade de um retinóide; método para proporcinar a libertação sustentada de um retinóide; método para aumentar a penetração na pele de um retinóide;método para aumentar a acumulação de tumor de encapsulamento de droga;método para reduzir a acumulação de drogas em tecidos de rolamento não tumorais; método para reduzir a toxicidade de um retinóide;método para reduzir a irritação da pele classificação de um retinóide aplicado topicamente encapsulante compreendendo uma pluralidade de nanopartículas;método de preparação de uma nanopartícula
US20120231072A1 (en) * 2011-03-11 2012-09-13 Chemisches Institut Schaefer Ag Thermo-responsive hydrogel compositions
CN103845278B (zh) * 2012-11-30 2016-06-22 沈阳药科大学 一种叶黄素眼用纳米乳-温度敏感型原位凝胶及其制备方法
MX388028B (es) * 2014-08-11 2025-03-19 Univ Louisiana State Suministro de antioxidantes bioactivos, nanoencapsulados.

Also Published As

Publication number Publication date
ZA201700987B (en) 2019-05-29
EP3179988A2 (en) 2017-06-21
EA201790361A1 (ru) 2017-06-30
AU2015301945A1 (en) 2017-03-09
CA2992879A1 (en) 2016-02-18
CA2992879C (en) 2022-10-25
US20190254987A1 (en) 2019-08-22
MX388028B (es) 2025-03-19
US20170216221A1 (en) 2017-08-03
AP2017009684A0 (https=) 2017-01-31
AU2015301945B2 (en) 2020-05-14
EP3179988A4 (en) 2018-11-14
JP6668327B2 (ja) 2020-03-18
WO2016025394A3 (en) 2016-05-19
EA035620B1 (ru) 2020-07-16
KR20170097601A (ko) 2017-08-28
US10292943B2 (en) 2019-05-21
JP2017523983A (ja) 2017-08-24
KR102218883B1 (ko) 2021-02-23
MX2017001903A (es) 2017-09-26
WO2016025394A2 (en) 2016-02-18
US10952974B2 (en) 2021-03-23

Similar Documents

Publication Publication Date Title
US10952974B2 (en) Delivery of bioactive, nanoencapsulated antioxidants
Chuacharoen et al. Stability and controlled release of lutein loaded in zein nanoparticles with and without lecithin and pluronic F127 surfactants
Yuan et al. Fabrication and characterization of lutein-loaded nanoparticles based on zein and sophorolipid: enhancement of water solubility, stability, and bioaccessibility
Bodoki et al. Topical nanodelivery system of lutein for the prevention of selenite-induced cataract
CN105828809B (zh) 包含脂质和活性药剂的具有聚合物涂层的微胶囊
CN113226293B (zh) 利用壳聚糖涂覆的纳米胶囊及其用途
JP7390738B2 (ja) キトサンでコートされたナノカプセル及びその用途
WO2016167732A1 (en) Development of curcumin and piperine loaded double-layered biopolymer based nano delivery systems by using electrospray / coating method
Deshmukh et al. Chitosan-vitamin C nanoparticles
US12383538B2 (en) Use of mTOR inhibitors for prevention of intestinal polyp growth and cancer
Das et al. Clinical management of eye diseases: carotenoids and their nanoformulations as choice of therapeutics
US20200000736A1 (en) Oil-free carotenoid composition
MXPA01012169A (es) Preparaciones para la aplicacion de agentes anti-infecciosos y/o anti-lamatorios para partes externas o internas del cuerpo humano o animal en la remodelacion funcional y cosmetica y tratamientos para reparacion de tejidos.
Mahajan et al. Development and evaluation of topical nanoemulgel formulation of tazarotene for effective treatment of excision wounds
Mehdipour Biregani et al. Curcumin as a bioactive compound: biological properties and encapsulation methods
Kumar et al. Therapeutic potential of Haematococcus pluvialis in the field of drug delivery
KR102384243B1 (ko) 레티놀 또는 레티놀 유도체를 포함하는 키토산이 코팅된 나노캡슐 및 이의 용도
JP6464745B2 (ja) 生理活性物質の担持力を向上させたナノ粒子の製造方法
Fayez et al. Fabrication of Curcumin and Voriconazole-Loaded Nanosponges Hydrogel for Topical Treatment of Candida albicans: In Vitro, Ex Vivo, and In Vivo Assessments
KR101771483B1 (ko) 루테인의 용출률 및 안정성이 개선된 이중층 구조의 고분자 캡슐, 이의 제조방법 및 이를 함유하는 안과질환 예방 또는 치료용 약제학적 조성물
Egea Bioavailability and Delivery Mechanisms of Nutraceuticals in Nanoparticles Derived from Biopolymers
Cosby Preclinical Delivery of Fractionated Black Raspberry Phytochemicals to Oral Epithelial Cells Using Lipid and Polymer Nanoparticles
Gad et al. Employment of Squash-synthesized Nanoselenium and Chitosan as Nanocomposites for Delivering Insulin
Toragall et al. Chitosan-sodium alginate-fatty acid nanocarrier composite: lutein bioavailability, absorption pharmacokinetics in diabetic rat and protection of retinal cells against H2O2 induced oxidative stress in vitro
Truong Development and Evaluation of Quercetin Nanoparticles and Hot Melt Cast Films for Retinal Neuroprotection

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]